Description
Cerillion is a leading provider of mission critical software for billing, charging and customer relationship management (“CRM”), predominantly serving the telecommunications market. The Company currently has over 90 customer installations across over 40 countries.
Headquartered in London, Cerillion also has operations in Pune, India, where its Global Solutions Centre is located, Miami, Sydney and Bulgaria, where it has recently opened an office.
Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a “one-stop shop” for Big Pharma seeking mid-stage products to licence or acquire. The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.
Insig is an AI and machine learning company that has developed a range of products to transform its clients’ competitiveness through unlocking the power of their data. The products integrate software, data science and cloud computing to help asset managers make better decisions, generate value, and manage their workflow more effectively. The products can be used alone or together.
Date: Monday, 22nd November
Time: 6 – 9:30pm
Speakers
- Louis Hall, CEO
-
Louis Hall is the CEO and founder of Cerillion, having led the management buyout of the original business from Logica in 1999. Louis has worked in the enterprise software industry for over 25 years and prior to forming Cerillion held a number of product, sales and management positions at Logica.
- Oliver Gilchrist, CFO
-
Oliver joined Cerillion in 2001 as CFO. He has over 30 years’ experience in finance, training as a chartered accountant at Coopers & Lybrand (now part of PWC). He left Coopers & Lybrand for industry in 1995 joining Parallax PLC as CFO, prior to its sale to Keane Inc in 1999 for $25m. Following this he acted as interim CFO for Apama Inc, managing a second round interim fundraise of $10m in 2001. The company was subsequently sold to the Carlyle Group.
- Jeremy Skillington, CEO
-
Jeremy began his biotechnology career in the Business Development group of Genentech, Inc in California in 2002. At Genentech he was responsible for executing over 40 licensing, investment and collaboration transactions. Returning to Ireland in 2009, he then led Business Development and was a member of the Senior Management team at Opsona Therapeutics Ltd before becoming a founder and CEO of immuno-oncology company TriMod Therapeutics Ltd.
| Ticket | Price |
|---|